Veracyte, Inc. (VCYT)

20,08 -0,95 (-4,52%) Ab 01:21PM EDT. Markt geöffnet.

Veracyte, Inc.

6000 Shoreline Court
Suite 300
South San Francisco, CA 94080
United States
650 243 6300
https://www.veracyte.com

Sektor(en): Healthcare
Branche: Diagnostics & Research
Vollzeitmitarbeiter: 815

Leitende Angestellte

Name	Titel	Zahlen	Ausgeübt	Geburtsjahr
Mr. Marc A. Stapley	CEO & Director	1,55M	N/A	1970
Ms. Rebecca Chambers	Executive VP & CFO	901,49k	N/A	1978
Dr. Phillip G. Febbo M.D.	Chief Scientific & Medical Officer	657,74k	N/A	1966
Ms. Annie McGuire	Executive VP, General Counsel & Chief People Officer	791,72k	N/A	1981
Dr. John Leite Ph.D.	Chief Commercial Officer for CLIA Business	1,53M	N/A	1972
Mr. Jonathan Wygant	VP & Chief Accounting Officer	N/A	N/A	1971
Mr. Steven French	Senior VP & Chief Information Officer	N/A	N/A	N/A
Ms. Karen Possemato	Senior Vice President of Corporate Marketing, Communications & Commercial Operations	N/A	N/A	N/A
Mr. Robert Brainin	Executive VP & Chief Business Officer	N/A	N/A	1971
Ms. Corinne Danan	Senior Vice President	N/A	N/A	N/A

Die Beträge haben den Stand 31. Dezember 2023 und Kompensationswerte gelten für das letzte Geschäftsjahr bis zu diesem Datum. Der Lohn umfasst Gehalt, Boni usw. „Ausgeübt“ entspricht dem Wert von Optionen, die im Lauf des Geschäftsjahrs ausgeübt werden. Währung in USD.

Beschreibung

Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.

Corporate Governance

Veracyte, Inc.s ISS Governance QualityScore, Stand 1. Mai 2024, lautet 4. Die grundlegenden Scores sind Audit: 6, Vorstand: 2, Shareholderrechte: 4, Kompensation: 7.

Corporate-Governance-Bewertungen von Institutional Shareholder Services (ISS). Die Werte geben den Zehntelwert im Verhältnis zum Index oder zur Region an. Ein Zehntelwert von 1 zeigt geringeres Governance-Risiko, 10 höheres Governance-Risiko.